Repository logo
 
Publication

A Review of National Guidelines for Management of COPD in Europe

2016-01-21Journal article Open access
Simple item page
dc.contributor.authorMiravitlles, M
dc.contributor.authorVogelmeier, C
dc.contributor.authorRoche, N
dc.contributor.authorHalpin, D
dc.contributor.authorCardoso, J
dc.contributor.authorChuchalin, A
dc.contributor.authorKankaanranta, H
dc.contributor.authorSandström, T
dc.contributor.authorŚliwiński, P
dc.contributor.authorZatloukal, J
dc.contributor.authorBlasi, F
dc.date.accessioned2016-01-26T15:47:36Z
dc.date.available2016-01-26T15:47:36Z
dc.date.issued2016-01-21
dc.description.abstractThe quality of care can be improved by the development and implementation of evidence-based treatment guidelines. Different national guidelines for chronic obstructive pulmonary disease (COPD) exist in Europe and relevant differences may exist among them.This was an evaluation of COPD treatment guidelines published in Europe and Russia in the past 7 years. Each guideline was reviewed in detail and information about the most important aspects of patient diagnosis, risk stratification and pharmacotherapy was extracted following a standardised process. Guidelines were available from the Czech Republic, England and Wales, Finland, France, Germany, Italy, Poland, Portugal, Russia, Spain and Sweden. The treatment goals, criteria for COPD diagnosis, consideration of comorbidities in treatment selection and support for use of long-acting bronchodilators, were similar across treatment guidelines. There were differences in measures used for stratification of disease severity, consideration of patient phenotypes, criteria for the use of inhaled corticosteroids and recommendations for other medications (e.g. theophylline and mucolytics) in addition to bronchodilators.There is generally good agreement on treatment goals, criteria for diagnosis of COPD and use of long-acting bronchodilators as the cornerstone of treatment among guidelines for COPD management in Europe and Russia. However, there are differences in the definitions of patient subgroups and other recommended treatments.pt_PT
dc.identifier.citationEur Respir J. 2016 Feb;47(2):625-37pt_PT
dc.identifier.doi10.1183/13993003.01170-2015pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/2371
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherEuropean Respiratory Societypt_PT
dc.subjectCHLC PNEUpt_PT
dc.subjectAdrenal Cortex Hormones/therapeutic usept_PT
dc.subjectBronchodilator Agents/therapeutic usept_PT
dc.subjectCzech Republic
dc.subjectDisease Management
dc.subjectEngland
dc.subjectEurope
dc.subjectEvidence-Based Medicine
dc.subjectExpectorants/therapeutic use
dc.subjectFinland
dc.subjectFrance
dc.subjectGermany
dc.subjectItaly
dc.subjectPatient Care Planning
dc.subjectPatient Selection
dc.subjectPoland
dc.subjectPortugal
dc.subjectPractice Guidelines as Topic
dc.subjectPulmonary Disease, Chronic Obstructive/diagnosis
dc.subjectPulmonary Disease, Chronic Obstructive/drug therapy
dc.subjectRussia
dc.subjectSpain
dc.subjectSweden
dc.subjectWales
dc.titleA Review of National Guidelines for Management of COPD in Europept_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.titleEuropean Respiratory Journalpt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ERJ.pdf
Size:
337.45 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

PNEU - Artigos